1. Home
  2. MRK vs RVMDW Comparison

MRK vs RVMDW Comparison

Compare MRK & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRK
  • RVMDW
  • Stock Information
  • Founded
  • MRK 2000
  • RVMDW N/A
  • Country
  • MRK United States
  • RVMDW United States
  • Employees
  • MRK N/A
  • RVMDW 490
  • Industry
  • MRK Biotechnology: Pharmaceutical Preparations
  • RVMDW
  • Sector
  • MRK Health Care
  • RVMDW
  • Exchange
  • MRK Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • MRK N/A
  • RVMDW N/A
  • IPO Year
  • MRK N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • MRK $87.31
  • RVMDW $0.12
  • Analyst Decision
  • MRK Buy
  • RVMDW
  • Analyst Count
  • MRK 15
  • RVMDW 0
  • Target Price
  • MRK $121.79
  • RVMDW N/A
  • AVG Volume (30 Days)
  • MRK 14.5M
  • RVMDW N/A
  • Earning Date
  • MRK 02-04-2025
  • RVMDW N/A
  • Dividend Yield
  • MRK 3.68%
  • RVMDW N/A
  • EPS Growth
  • MRK 4711.66
  • RVMDW N/A
  • EPS
  • MRK 6.74
  • RVMDW N/A
  • Revenue
  • MRK $64,168,000,000.00
  • RVMDW N/A
  • Revenue This Year
  • MRK $5.72
  • RVMDW N/A
  • Revenue Next Year
  • MRK $5.97
  • RVMDW N/A
  • P/E Ratio
  • MRK $12.96
  • RVMDW N/A
  • Revenue Growth
  • MRK 6.74
  • RVMDW N/A
  • 52 Week Low
  • MRK $87.20
  • RVMDW N/A
  • 52 Week High
  • MRK $134.63
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • MRK 26.67
  • RVMDW N/A
  • Support Level
  • MRK $87.33
  • RVMDW N/A
  • Resistance Level
  • MRK $100.15
  • RVMDW N/A
  • Average True Range (ATR)
  • MRK 2.10
  • RVMDW 0.00
  • MACD
  • MRK -1.10
  • RVMDW 0.00
  • Stochastic Oscillator
  • MRK 1.46
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: